Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Amlitelimab for Atopic Dermatitis (SHORE)
Recruiting1 awardPhase 3
Tulsa, Oklahoma
The purpose of the SHORE Study is to test how well and safely a new investigational drug called amlitelimab works in participants with atopic dermatitis (AD) who are on concomitant background topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.